News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunogen Inc
(NQ:
IMGN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immunogen Inc
< Previous
1
2
3
4
5
Next >
ImmunoGen Inc. (NASDAQ: IMGN) Near Top of Volume Charts in Thursday Trading
February 08, 2024
Via
Investor Brand Network
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2024
From
ImmunoGen, Inc.
Via
Business Wire
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
Via
Get News
Exposures
Product Safety
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug...
Via
TheNewswire.com
Exposures
Product Safety
ImmunoGen Inc. (NASDAQ: IMGN) Near Top of Volume Charts in Thursday Trading
November 30, 2023
Via
Investor Brand Network
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2024
From
ImmunoGen, Inc.
Via
Business Wire
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
December 29, 2023
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.
Via
MarketBeat
AbbVie continues shopping spree with biotech buyout
December 12, 2023
While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend.
Via
MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc.
December 11, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH
December 10, 2023
From
ImmunoGen Inc.
Via
Business Wire
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
December 05, 2023
From
ImmunoGen, Inc.
Via
Business Wire
IMMUNOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ImmunoGen, Inc. - IMGN
December 04, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hawaiian Holdings, Inc. (Nasdaq – HA), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
December 04, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
IMGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ImmunoGen, Inc. Is Fair to Shareholders
November 30, 2023
From
Halper Sadeh LLC
Via
Business Wire
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference
November 02, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
November 02, 2023
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2023
From
ImmunoGen, Inc.,
Via
Business Wire
ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
October 27, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results
October 19, 2023
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer
September 28, 2023
From
ImmunoGen Inc.
Via
Business Wire
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
September 20, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 20, 2023 – USA News Group – Earlier this year, the US White House requested over $2.8 billion in funding from Congress...
Via
FinancialNewsMedia
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 18, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
September 18, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 05, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan
August 28, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer
July 31, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results
July 31, 2023
From
ImmunoGen, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.